Thailand’s Food and Drug Administration has approved ravidasvir as a treatment for hepatitis C, to be used in combination with sofosbuvir as part of the country’s broader elimination strategy.

• Treatment regimen: Oral combination therapy taken once daily for 12 weeks alongside sofosbuvir.
• Clinical data: Demonstrated efficacy in Thailand and Malaysia, resulting in complete cure in treated patients.
• Development: Research and manufacturing involved Pharco Pharmaceuticals, DNDi, and public health institutions in Thailand and Malaysia.

This summary is based on a press release reported by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.